Abdulmohsen AlMusaad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Abdulmohsen AlMusaad has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Mareyah Alshaikh Husain2 shared publications
Raed Sweidan
King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia
2 shared publications- Zainab Albahrani2 shared publications
Abdelrahman Jamiel
King Abdalaziz Medical City -National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia
1 shared publication- Abdulelah H. Alsaeed
Department of Cardiac Sciences, College of Medicine, King Saud University, Riyadh, Saudi Arabia
1 shared publication - Abdullah Dhawi Al-Otaibi1 shared publication
Latest Publications
- Open Access
- 11 June 2024
- Published by IntechOpen
Synchronizing Beats: From Theory to Advances and Insight in Cardiac Resynchronization Therapy
Cardiac resynchronization therapy (CRT) is an established treatment for select patients with systolic heart failure, left ventricular conduction delay, and dyssynchronous contraction. Landmark trials have shown CRT’s benefits on symptoms, exercise capacity, reverse remodeling, hospitalization rates, and mortality. However, limitations exist including sub-optimal patient selection, procedural complexity, high non-responder rates, and device-related adverse effects. This review summarizes the evolution, physiology, clinical trial evidence, patient selection, delivery, and optimization of CRT. Key areas covered include guidelines for CRT use, invasive and noninvasive imaging to improve outcomes, alternative pacing sites to enhance response, and advances in lead technology and implantation techniques. Gaps in current knowledge are highlighted along with future directions for research to refine CRT utilization and improve real-world clinical outcomes. With further studies to address remaining questions, CRT is poised to become an even more effective therapy for heart failure patients with dyssynchronous cardiomyopathy.
- 11 June 2024
- Published by IntechOpen
Open AccessSynchronizing Beats: From Theory to Advances and Insight in Cardiac Resynchronization Therapy
Cardiac resynchronization therapy (CRT) is an established treatment for select patients with systolic heart failure, left ventricular conduction delay, and dyssynchronous contraction. Landmark trials have shown CRT’s benefits on symptoms, exercise capacity, reverse remodeling, hospitalization rates, and mortality. However, limitations exist including sub-optimal patient selection, procedural complexity, high non-responder rates, and device-related adverse effects. This review summarizes the evolution, physiology, clinical trial evidence, patient selection, delivery, and optimization of CRT. Key areas covered include guidelines for CRT use, invasive and noninvasive imaging to improve outcomes, alternative pacing sites to enhance response, and advances in lead technology and implantation techniques. Gaps in current knowledge are highlighted along with future directions for research to refine CRT utilization and improve real-world clinical outcomes. With further studies to address remaining questions, CRT is poised to become an even more effective therapy for heart failure patients with dyssynchronous cardiomyopathy.
- Open Access
- 8 January 2024
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 19 (1) , 40
The Average Age of Atrioventricular Block Onset in Middle Eastern Patients with Cardiac Rhythm Devices Adjusted for the Overall Young Population: Insights from a Multicenter International Registry
Background: Previous registries have shown a younger average age at presentation with cardiovascular diseases in the Middle East (ME), but no study has examined atrioventricular block (AVB). Moreover, these comparisons are confounded by younger populations in the ME. We sought to describe the average age at presentation with AVB in ME and quantify the effect of being from ME, adjusted for the overall younger population. Methodology: This was a retrospective analysis of PANORAMA registries, which collected data on patients who underwent cardiac rhythm device placement worldwide. Countries with a median population age of ≤30 were considered ‘young countries’. Multivariate linear regression was performed to assess the effect of being from ME, adjusted for being from a ‘young country’, on age at presentation with AVB. Results: The study included 5,259 AVB patients, with 640 (8.2%) from the ME. Mean age at presentation was seven years younger in ME than in other regions (62.9 ± 17.8 vs. 70 ± 14.1, P < 0.001). Being from a ‘young country’ was associated with 5.6 years younger age at presentation (95%CI –6.5––4.6), whereas being from ME was associated with 3.1 years younger age at presentation (95%CI –4.5––1.8), (P < 0.001 for both). Conclusion: The average age at presentation with AVB in the ME is seven years younger than in other regions. While this is mostly driven by the overall younger population, being from the ME appears to be independently associated with younger age. Determinants of the earlier presentation in ME need to be assessed, and care should be taken when applying international recommendations.
- 8 January 2024
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 19 (1) , 40
Open AccessThe Average Age of Atrioventricular Block Onset in Middle Eastern Patients with Cardiac Rhythm Devices Adjusted for the Overall Young Population: Insights from a Multicenter International Registry
Background: Previous registries have shown a younger average age at presentation with cardiovascular diseases in the Middle East (ME), but no study has examined atrioventricular block (AVB). Moreover, these comparisons are confounded by younger populations in the ME. We sought to describe the average age at presentation with AVB in ME and quantify the effect of being from ME, adjusted for the overall younger population. Methodology: This was a retrospective analysis of PANORAMA registries, which collected data on patients who underwent cardiac rhythm device placement worldwide. Countries with a median population age of ≤30 were considered ‘young countries’. Multivariate linear regression was performed to assess the effect of being from ME, adjusted for being from a ‘young country’, on age at presentation with AVB. Results: The study included 5,259 AVB patients, with 640 (8.2%) from the ME. Mean age at presentation was seven years younger in ME than in other regions (62.9 ± 17.8 vs. 70 ± 14.1, P < 0.001). Being from a ‘young country’ was associated with 5.6 years younger age at presentation (95%CI –6.5––4.6), whereas being from ME was associated with 3.1 years younger age at presentation (95%CI –4.5––1.8), (P < 0.001 for both). Conclusion: The average age at presentation with AVB in the ME is seven years younger than in other regions. While this is mostly driven by the overall younger population, being from the ME appears to be independently associated with younger age. Determinants of the earlier presentation in ME need to be assessed, and care should be taken when applying international recommendations.
- Open Access
- 20 December 2023
- Published by MDPI AG in Preprints.org
An In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID19-Associated Cardiovascular Ailments for Identifying Novel Disease Biomarkers, Drug Targets and Clinical Management Strategies
Background: COVID-19 was initially identified as a respiratory system disorder, but it has been discovered to interact with and influence the cardiovascular system. COVID-19-associated cardiovascular (CV) complications are common, resulting in high acute phase mortality and a large number of morbidities in the chronic phase, thus severely impacting patients' quality of life and health outcomes. Nevertheless, clinical, cellular, and molecular biological factors underlying the pathophysiology of cardiovascular complications associated with COVID-19 are poorly understood. Objective: This review investigates putative underlying clinical factors as well as cellular and molecular biological mechanisms by which COVID-19 leads to acute CV complications, including state-of-the-art genomic sequencing-based findings, assessing the long-term CV consequences of COVID-19, and aiming to shed light on developing strategies for differential diagnosis, risk prognostic stratification, prevention, and clinical management of CV sequlea in COVID-19 patients. Methods: For this purpose, a through review of literature and published data was carried out from first report of COVID-19 till October 2023 to find out a comprehensive account of clinical, cellular and molecular genetic factors underlying COVID-19-associated cardiovascular diseases. Results: We found that the relationship between COVID-19 and CV risk is complex and multifaceted. In addition to acute COVID-19 detertriuos effects, COVID-19 survivors may experience long-term CV effects. We provide a detailed account of the involvement of a large number of genomic alterations, microRNAs, and novel viral as well as host proteins in CVDs associated with COVID-19, which has helped identify some novel drug targets to treat COVID-19-related cardiovascular complications. Conclusions: The relationship between COVID-19 and CV risk is complex and multifaceted. While COVID-19 primarily affects the respiratory system, it can also significantly affect CV health. as compared to classical cardiovascular diseases, there are new clinical, cellular and molecular biological factors in CVDs related to COVID-19, that need specific diagnostic assays, prognostic stratification and treatment modules. Therefore, specail care is must taken to treat cardiovascular diseases associated with COVID-19.
- 20 December 2023
- Published by MDPI AG in Preprints.org
Open AccessAn In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID19-Associated Cardiovascular Ailments for Identifying Novel Disease Biomarkers, Drug Targets and Clinical Management Strategies
Background: COVID-19 was initially identified as a respiratory system disorder, but it has been discovered to interact with and influence the cardiovascular system. COVID-19-associated cardiovascular (CV) complications are common, resulting in high acute phase mortality and a large number of morbidities in the chronic phase, thus severely impacting patients' quality of life and health outcomes. Nevertheless, clinical, cellular, and molecular biological factors underlying the pathophysiology of cardiovascular complications associated with COVID-19 are poorly understood. Objective: This review investigates putative underlying clinical factors as well as cellular and molecular biological mechanisms by which COVID-19 leads to acute CV complications, including state-of-the-art genomic sequencing-based findings, assessing the long-term CV consequences of COVID-19, and aiming to shed light on developing strategies for differential diagnosis, risk prognostic stratification, prevention, and clinical management of CV sequlea in COVID-19 patients. Methods: For this purpose, a through review of literature and published data was carried out from first report of COVID-19 till October 2023 to find out a comprehensive account of clinical, cellular and molecular genetic factors underlying COVID-19-associated cardiovascular diseases. Results: We found that the relationship between COVID-19 and CV risk is complex and multifaceted. In addition to acute COVID-19 detertriuos effects, COVID-19 survivors may experience long-term CV effects. We provide a detailed account of the involvement of a large number of genomic alterations, microRNAs, and novel viral as well as host proteins in CVDs associated with COVID-19, which has helped identify some novel drug targets to treat COVID-19-related cardiovascular complications. Conclusions: The relationship between COVID-19 and CV risk is complex and multifaceted. While COVID-19 primarily affects the respiratory system, it can also significantly affect CV health. as compared to classical cardiovascular diseases, there are new clinical, cellular and molecular biological factors in CVDs related to COVID-19, that need specific diagnostic assays, prognostic stratification and treatment modules. Therefore, specail care is must taken to treat cardiovascular diseases associated with COVID-19.
- Open Access
- 22 June 2021
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 63 (2) , 399-407
Long-term reverse remodeling and clinical improvement by MultiPoint Pacing in a randomized, international, Middle Eastern heart failure study
Purpose: Cardiac resynchronization therapy (CRT) with multipoint left ventricular (LV) pacing (MultiPoint™ Pacing, MPP) has been shown to improve CRT response, although MPP response using automated pacing vector programming has not been demonstrated in the Middle East. The purpose of this study was to compare the impact of MPP to conventional biventricular pacing (BiV) using echocardiographic and clinical changes at 6-month post-implant. Methods: This prospective, randomized study was conducted at 13 Middle Eastern centers. After de novo CRT-D implant (Abbott Unify Quadra MP™ or Quadra Assura MP™) with quadripolar LV lead (Abbott Quartet™), patients were randomized to either BiV or MPP therapy. In BiV patients, the LV pacing vector was selected per standard practice; in MPP patients, the two LV pacing vectors were selected automatically using VectSelect. CRT response was defined at 6-month post-implant by a reduction in LV end-systolic volume (ESV) ≥ 15%. Results: One hundred and forty-two patients (61 years old, 68% male, NYHA class II/III/IV 19%/75%/6%, 33% ischemic, 57% hypertension, 52% diabetes, 158 ms QRS, 25.8% ejection fraction [EF]) were randomized to either BiV (N = 69) or MPP (N = 73). After 6 months, MPP vs. BiV patients experienced greater ESV reduction (25.0% vs. 15.3%, P = 0.08), greater EF improvement (11.9% vs. 8.6%, P = 0.36), significantly greater ESV response rate (68.5% vs. 50.7%, P = 0.04), and significantly greater NYHA class improvement rate (80.8% vs. 60.3%, P = 0.01). Conclusions: With MPP and automatic LV vector selection, more CRT patients in the Middle East experienced reverse remodeling and clinical improvement relative to conventional BiV pacing.
- 22 June 2021
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 63 (2) , 399-407
Open AccessLong-term reverse remodeling and clinical improvement by MultiPoint Pacing in a randomized, international, Middle Eastern heart failure study
Purpose: Cardiac resynchronization therapy (CRT) with multipoint left ventricular (LV) pacing (MultiPoint™ Pacing, MPP) has been shown to improve CRT response, although MPP response using automated pacing vector programming has not been demonstrated in the Middle East. The purpose of this study was to compare the impact of MPP to conventional biventricular pacing (BiV) using echocardiographic and clinical changes at 6-month post-implant. Methods: This prospective, randomized study was conducted at 13 Middle Eastern centers. After de novo CRT-D implant (Abbott Unify Quadra MP™ or Quadra Assura MP™) with quadripolar LV lead (Abbott Quartet™), patients were randomized to either BiV or MPP therapy. In BiV patients, the LV pacing vector was selected per standard practice; in MPP patients, the two LV pacing vectors were selected automatically using VectSelect. CRT response was defined at 6-month post-implant by a reduction in LV end-systolic volume (ESV) ≥ 15%. Results: One hundred and forty-two patients (61 years old, 68% male, NYHA class II/III/IV 19%/75%/6%, 33% ischemic, 57% hypertension, 52% diabetes, 158 ms QRS, 25.8% ejection fraction [EF]) were randomized to either BiV (N = 69) or MPP (N = 73). After 6 months, MPP vs. BiV patients experienced greater ESV reduction (25.0% vs. 15.3%, P = 0.08), greater EF improvement (11.9% vs. 8.6%, P = 0.36), significantly greater ESV response rate (68.5% vs. 50.7%, P = 0.04), and significantly greater NYHA class improvement rate (80.8% vs. 60.3%, P = 0.01). Conclusions: With MPP and automatic LV vector selection, more CRT patients in the Middle East experienced reverse remodeling and clinical improvement relative to conventional BiV pacing.
- Open Access
- 1 November 2014
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 16 (suppl B) , B84-B88
Ivabradine maintains sinus rhythm and reverses atrial tachycardia-induced cardiomyopathy
Atrial tachycardia resistant to conventional management may respond to ivabradine. Two cases of resistant tachycardia are presented that responded to ivabradine. Both cases were later successfully ablated and both maintained sinus rhythm and are symptom free 2 years post procedure. The physiological mechanism for this is also briefly discussed.
- 1 November 2014
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 16 (suppl B) , B84-B88
Open AccessIvabradine maintains sinus rhythm and reverses atrial tachycardia-induced cardiomyopathy
Atrial tachycardia resistant to conventional management may respond to ivabradine. Two cases of resistant tachycardia are presented that responded to ivabradine. Both cases were later successfully ablated and both maintained sinus rhythm and are symptom free 2 years post procedure. The physiological mechanism for this is also briefly discussed.